Ocular Therapeutix™ to Participate in October Scientific and Investor Conferences
Key Highlights
- ➤Ocular Therapeutix (OCUL) to present SOL-1 Phase 3 wet AMD trial data at October conferences
- ➤AXPAXLI (OTX-TKI) remains in Phase 3 trials for wet AMD and diabetic retinal disease
- ➤SOL-1 presentation covers topline outcomes from sustained hydrogel delivery in neovascular AMD
- ➤Chardan fireside chat features CEO Pravin U. Dugel on October 20, 2026
Expert Statements
Pravin U. Dugel, Executive Chairman, President and CEO of Ocular Therapeutix
“Redefining the Retina Experience”
Arshad M. Khanani, Presenter at Innovate Retina and American Academy of Ophthalmology
“Sustained Hydrogel Delivery in Neovascular AMD: Topline Outcomes from the Phase 3 SOL-1 Trial with Hydrogel-Formulated Axpaxli”
Darius M. Moshfeghi, Presenter at American Academy of Ophthalmology Retina Subspeciality Day
“Phase 3 Trial of OTX-TKI (SOL-1) for Wet AMD”
Mark R. Barakat, Presenter at American Academy of Ophthalmology
“SOL-1 Phase 3 Superiority Trial Evaluating Intravitreal Axitinib Hydrogel (OTX-TKI) in nAMD”
BEDFORD, Mass., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced participation in several upcoming scientific and investor conferences in October 2026.
Chardan 10(th) Annual Healthcare Conference: Date: Tuesday, October 20, 2026 Fireside Chat: 9:45 AM ET Presenter: Pravin U. Dugel, MD, Executive Chairman, President and CEO Location: New York, NY
Get started
Create a free account to read the full story.